maintenance after tirzepatide What are the doses of (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist) for a patient who has reached their goal weight? Tirzepatide weight loss maintenance study

Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future

Treatments can be performed on the buttocks, abdomen, arms, and thighs

Lifestyle factors also play a huge role

Most patients at Perfect B begin noticing meaningful cognitive improvements between weeks two and three of the protocol

Nearly 1 in 3 users (29%) reported feeling under-supported during their first 30 days